Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
M	O
Service:	O
MEDICINE	O
Allergies:	O
Bactrim	O
Attending:	O
___.	O
Chief	O
Complaint:	O
Fever	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
Bone	O
Marrow	O
Biopsy	O
(___)	O
History	O
of	O
Present	O
Illness:	O
Mr.	O
___	O
is	O
an	O
___	O
male	O
with	O
MDS	O
transformed	O
to	O
AML	O
on	O
decitabine/venetoclax,	O
diastolic	O
congestive	O
heart	O
failure,	O
polyarticular	O
pseudogout,	O
and	O
myasthenia	O
___	O
(on	O
chronic	O
prednisone)	O
who	O
presents	O
with	O
fever.	O
Patient	O
reports	O
that	O
he	O
developed	O
chills	O
earlier	O
this	O
evening	O
with	O
fever	O
to	O
100.0.	O
Had	O
one	O
loose	O
stool.	O
He	O
denies	O
recent	O
travel.	O
He	O
denies	O
sick	O
contacts.	O
He	O
was	O
seen	O
in	O
clinic	O
yesterday	O
and	O
had	O
blood	O
and	O
platelet	O
transfusions.	O
On	O
arrival	O
to	O
the	O
ED,	O
initial	O
vitals	O
were	O
102.7	O
105	O
137/81	O
16	O
96%	O
RA.	O
Exam	O
was	O
unremarkable.	O
Labs	O
were	O
notable	O
for	O
WBC	O
0.9	O
(ANC	O
170),	O
H/H	O
7.6/23.7,	O
Plt	O
13,	O
Na	O
137,	O
K	O
4.2,	O
BUN/Cr	O
___,	O
and	O
lactate	O
2.7.	O
Blood	O
cultures	O
were	O
sent.	O
CXR	O
was	O
negative	O
for	O
pneumonia.	B-Lower_gastrointestinal_haemorrhage
Patient	O
was	O
given	O
cefepime.	O
Unclear	O
if	O
was	O
given	O
Tylenol	O
(received	O
1g	O
per	O
wife	O
but	O
not	O
ordered	O
in	O
POE	O
or	O
documented	O
in	O
___.	O
Prior	O
to	O
transfer	O
vitals	O
were	O
102.8	O
84	O
132/86	O
16	O
95%	O
RA.	O
On	O
arrival	O
to	O
the	O
floor,	O
patient	O
reports	O
feeling	O
weak.	O
He	O
has	O
no	O
acute	O
complaints.	O
He	O
denies	O
any	O
viral	O
symptoms.	O
He	O
denies	O
headache,	O
vision	B-Visual_impairment
changes,	B-Visual_impairment
dizziness/lightheadedness,	O
weakness/numbnesss,	O
shortness	O
of	O
breath,	O
cough,	O
hemoptysis,	O
chest	O
pain,	O
palpitations,	O
abdominal	O
pain,	O
nausea/vomiting,	O
hematemesis,	B-Upper_gastrointestinal_haemorrhage
hematochezia/melena,	B-Lower_gastrointestinal_haemorrhage
dysuria,	O
hematuria,	O
and	O
new	O
rashes.	O
REVIEW	O
OF	O
SYSTEMS:	O
A	O
complete	O
10-point	O
review	O
of	O
systems	O
was	O
performed	O
and	O
was	O
negative	O
unless	O
otherwise	O
noted	O
in	O
the	O
HPI.	O
Past	O
Medical	O
History:	O
PAST	O
ONCOLOGIC	O
HISTORY:	O
-	O
___:	O
Evaluated	O
by	O
Dr.	O
___	O
Atrius	O
___	O
for	O
new	O
macroytic	O
anemia.	O
-	O
___:	O
Bone	O
marrow	O
biopsy	O
reveals	O
hypercellular	O
bone	O
marrow	O
with	O
myeloid	O
predominant	O
trilineage	O
hematopoiesis,	O
abnormal	O
megakaryocytes	O
and	O
mild	O
erythroid	O
and	O
myeloid	O
dysplasia,	O
suspicious	O
for	O
involvement	O
by	O
an	O
evolving	O
myelodysplastic	O
syndrome.	O
R-IPSS	O
score	O
2.0	O
(low	O
risk).	O
Initiates	O
PRBC	O
transfusions	O
as	O
needed.	O
-	O
___:	O
Begins	O
darbepoetin	O
300	O
mcg	O
twice	O
weekly,	O
increased	O
to	O
500	O
mcg	O
twice	O
weekly	O
after	O
little	O
response.	O
-	O
___:	O
Repeat	O
bone	O
marrow	O
biopsy	O
reveals	O
dysplastic	O
myeloid	O
erythroid	O
and	O
megakaryocytes.	O
There	O
was	O
not	O
an	O
increased	O
number	O
of	O
blasts	O
in	O
the	O
marrow	O
though	O
he	O
does	O
have	O
occasional	O
blasts	O
in	O
his	O
peripheral	O
blood	O
smears.	O
His	O
cytogenetics	O
were	O
entirely	O
normal;	O
he	O
was	O
46	O
XY	O
karyotype.	O
The	O
usual	O
MDS	O
panel	O
was	O
performed	O
and	O
was	O
negative	O
by	O
fish.	O
-	O
___:	O
C1D1	O
azacitidine	O
(only	O
receives	O
4	O
doses).	O
-	O
___:	O
C2D1	O
azacytidine.	O
-	O
___:	O
C3D1	O
azacitidine	O
(only	O
receives	O
2	O
doses).	O
-	O
___:	O
C4D1	O
azacitidine	O
(only	O
receives	O
3	O
doses).	O
-	O
___:	O
Begins	O
lenalidomide	O
10	O
mg	O
daily.	O
Held	O
intermittently	O
for	O
fever	O
and	O
pseudogout.	O
-	O
___:	O
Lenalidomide	O
held	O
on	O
a	O
permanent	O
basis.	O
-	O
___:	O
Develops	O
1-5%	O
peripheral	O
blasts.	O
-	O
___:	O
C1D1	O
decitabine	O
20	O
mg/m2	O
x	O
5	O
days.	O
-	O
___:	O
C2D1	O
decitabine	O
20	O
mg/m2	O
x	O
5	O
days.	O
-	O
___:	O
Repeat	O
bone	O
marrow	O
aspiration	O
and	O
biopsy	O
reveals	O
hypercellular	O
bone	O
marrow	O
with	O
involvement	O
by	O
known	O
MDS,	O
5%	O
blasts	O
by	O
immunohistochemistry	O
and	O
flow	O
cytometry,	O
normal	O
male	O
karyotype,	O
FISH	O
negative	O
for	O
common	O
MDS	O
abnormalities,	O
molecular	O
analysis	O
with	O
mutations	O
in	O
TET2,	O
KIT,	O
EZH2,	O
NF1,	O
STAG2,	O
and	O
SETD2.	O
-	O
___:	O
C3D1	O
decitabine	O
20	O
mg/m2	O
x	O
5	O
days.	O
-	O
___:	O
C4D1	O
decitabine	O
20	O
mg/m2	O
x	O
5	O
days.	O
-	O
___:	O
Repeat	O
bone	O
marrow	O
aspiration	O
and	O
biopsy	O
reveals	O
hypercellular	O
myeloid	O
predominant	O
marrow	O
with	O
trilineage	O
dysplasia	O
and	O
increased	O
blasts	O
___	O
by	O
morphology	O
and	O
flow	O
cytometry,	O
respectively),	O
normal	O
male	O
karyotype,	O
molecular	O
analysis	O
with	O
mutations	O
in	O
TET2,	O
STAG2,	O
EZH2,	O
SETD2,	O
KIT,	O
and	O
NF1.	O
-	O
___:	O
C5D1	O
decitabine	O
20	O
mg/m2	O
x	O
5	O
days.	O
-	O
___:	O
C6D1	O
decitabine	O
20	O
mg/m2	O
x	O
4	O
days(abbreviated	O
length	O
due	O
to	O
pt	O
travel	O
plans).	O
-	O
___:	O
C7D1	O
decitabine	O
20	O
mg/m2	O
x	O
5	O
days.	O
-	O
___:	O
C8D1	O
decitabine	O
20	O
mg/m2	O
x	O
4	O
days.	O
-	O
___:	O
C9D1	O
decitabine	O
20	O
mg/m2	O
x	O
5	O
days.	O
-	O
___:	O
C10D1	O
decitabine	O
20	O
mg/m2	O
x	O
5	O
days.	O
-	O
___:	O
Right	O
port	O
removal	O
due	O
to	O
port	O
being	O
exposed.	O
New	O
left	O
chest	O
port	O
placement.	O
-	O
___:	O
Admission	O
for	O
fever	O
and	O
cough,	O
diagnosed	O
with	O
community-acquired	B-Lower_respiratory_tract_infection
pneumonia	B-Lower_respiratory_tract_infection
or	O
consolidation	O
seen	O
on	O
chest	O
CT.	O
improvement	O
with	O
cefepime,	O
transition	O
to	O
Levaquin	O
to	O
complete	O
7-day	O
course	O
on	O
___.	O
Viral	O
PCR	O
panel	O
negative	O
from	O
NP	O
swab.	O
-	O
___:	O
C11D1	O
decitabine	O
20	O
mg/m2	O
x	O
5	O
days.	O
-	O
___:	O
Peripheral	O
blasts	O
persistently	O
___.	O
-	O
___:	O
Surveillance	O
bone	O
marrow	O
biopsy	O
reveals	O
a	O
hypercellular	O
bone	O
marrow	O
with	O
involvement	O
by	O
AML	O
with	O
MDS-related	O
changes.	O
Karytotype	O
and	O
AML	O
FISH	O
panels	O
are	O
normal.	O
Molecular	O
sequencing	O
remains	O
PENDING.	O
-	O
___:	O
C1D1	O
Decitabine/Venetoclax.	O
-	O
___:	O
Initiates	O
Venetoclax	O
100	O
mg	O
daily.	O
-	O
___:	O
Increases	O
Venetoclax	O
to	O
200	O
mg	O
daily	O
(target	O
dose).	O
PAST	O
MEDICAL	O
HISTORY:	O
-	O
Myelodysplastic	O
Syndrome	O
with	O
evolution	O
to	O
Acute	O
Myelogenous	O
Leukemia,	O
as	O
above.	O
-	O
Diastolic	O
Congestive	O
Heart	O
Failure	O
-	O
Polyarticular	O
Pseudogout	O
-	O
Myasthenia	O
___	O
(Diagnosed	O
about	O
___	O
years	O
ago.	O
Presented	O
with	O
right	B-Visual_impairment
eye	B-Visual_impairment
closure	B-Visual_impairment
(ptosis),	O
tongue	O
swelling.	O
The	O
symptoms	O
occur	O
very	O
infrequently.	O
Followed	O
by	O
Dr.	O
___	O
at	O
___).	O
-	O
Hypertension	O
-	O
Hypothyroidism	O
-	O
Vitamin	O
D	O
Deficiency	O
-	O
Colon	O
Polyps	O
-	O
Intervertebral	O
Lumbar	O
Disc	O
Disorder	O
with	O
myelopathy,	O
lumbar	O
region	O
-	O
Seborrheic	O
Keratosis	O
-	O
Actinic	O
Keratosis	O
-	O
Basal	O
Cell	O
Carcinoma	O
-	O
Squamous	O
Cell	O
Carcinoma,	O
followed	O
by	O
dermatologist	O
Dr.	O
___	O
at	O
___	O
in	O
___	O
-	O
Venous	O
Tributary	O
(branch)	O
Occlusion	B-Visual_impairment
of	B-Visual_impairment
Retina	B-Visual_impairment
-	O
s/p	O
hernia	O
repair	O
x	O
___	O
-	O
s/p	O
right	O
knee	O
replacement	O
Social	O
History:	O
___	O
Family	O
History:	O
Father-rheumatic	O
fever	O
___	O
disease	O
Maternal	O
grandmother-colon	O
cancer	O
No	O
family	O
history	O
of	O
hematologic	O
disorder	O
Physical	O
Exam:	O
ADMISSION	O
PHYSICAL	O
EXAM:	O
VS:	O
Temp	O
102.3,	O
BP	O
115/57,	O
HR	O
83,	O
RR	O
18,	O
O2	O
sat	O
95%	O
RA.	O
GENERAL:	O
Very	O
pleasant	O
man,	O
in	O
no	O
distress,	O
lying	O
in	O
bed	O
comfortably.	O
HEENT:	O
Anicteric,	O
PERLL,	O
OP	O
clear,	O
temporal	O
wasting.	O
CARDIAC:	O
RRR,	O
normal	O
s1/s2,	O
no	O
m/r/g.	O
LUNG:	O
Appears	O
in	O
no	O
respiratory	O
distress,	O
clear	O
to	O
auscultation	O
bilaterally,	O
no	O
crackles,	O
wheezes,	O
or	O
rhonchi.	O
ABD:	O
Soft,	O
non-tender,	O
non-distended,	O
positive	O
bowel	O
sounds.	O
EXT:	O
Warm,	O
well	O
perfused,	O
no	O
lower	O
extremity	O
edema.	O
NEURO:	O
A&Ox3,	B-Delirium
good	O
attention	O
and	O
linear	O
thought,	O
gross	O
strength	O
and	O
sensation	O
intact.	O
SKIN:	O
No	O
significant	O
rashes.	O
ACCESS:	O
Left	O
chest	O
wall	O
port	O
without	O
erythema.	O
DISCHARGE	O
PHYSICAL	O
EXAM	O
___	O
0642	O
Temp:	O
97.8	O
PO	O
BP:	O
152/66	O
HR:	O
54	O
RR:	O
16	O
O2	O
sat:	O
97%	O
O2	O
delivery:	O
RA	O
GENERAL:	O
Older	O
man	O
in	O
NAD	O
HEENT:	O
NCAT,	O
sclerae	O
anicteric,	O
oropharynx	O
clear,	O
MMM	O
CARDIAC:	O
RRR,	O
normal	O
s1/s2,	O
no	O
m/r/g	O
LUNG:	O
Decreased	O
breath	O
sounds	O
at	O
L	O
base	O
(comparable	O
to	O
prior),	O
otherwise	O
CTAB,	O
no	O
increased	O
work	O
of	O
breathing	O
ABD:	O
Soft,	O
non-tender,	O
non-distended,	O
normoactive	O
BS	O
EXT:	O
Warm,	O
DP	O
pulses	O
2+	O
bilaterally,	O
no	O
edema	O
NEURO:	O
A&Ox3,	B-Delirium
good	O
attention	O
and	O
linear	O
thought	O
SKIN:	O
No	O
significant	O
rashes	O
BACK:	O
No	O
evidence	O
of	O
hematoma	O
or	O
infection	O
at	O
biopsy	O
site	O
ACCESS:	O
Left	O
chest	O
wall	O
port	O
without	O
erythema	O
Pertinent	O
Results:	O
ADMISSION	O
LABS:	O
___	O
10:35PM	O
BLOOD	O
WBC:	O
0.9*	O
RBC:	O
2.71*	O
Hgb:	O
7.6*	O
Hct:	O
23.7*	O
MCV:	O
88	O
MCH:	O
28.0	O
MCHC:	O
32.1	O
RDW:	O
14.2	O
RDWSD:	O
44.___*	O
___	O
10:35PM	O
BLOOD	O
Neuts:	O
19*	O
Lymphs:	O
65*	O
Monos:	O
7	O
Eos:	O
7	O
Baso:	O
0	O
Atyps:	O
1*	O
Myelos:	O
1*	O
AbsNeut:	O
0.17*	O
AbsLymp:	O
0.59*	O
AbsMono:	O
0.06*	O
AbsEos:	O
0.06	O
AbsBaso:	O
0.00*	O
___	O
10:35PM	O
BLOOD	O
Glucose:	O
105*	O
UreaN:	O
29*	O
Creat:	O
1.1	O
Na:	O
137	O
K:	O
4.2	O
Cl:	O
101	O
HCO3:	O
23	O
AnGap:	O
13	O
___	O
10:49PM	O
BLOOD	O
Lactate:	O
2.7*	O
PERTINENT	O
STUDIES:	O
___	O
Imaging	O
CT	O
SINUS/MANDIBLE/MAXIL	O
Moderate	O
mucosal	O
thickening	O
within	O
the	O
right	O
sphenoid	O
sinus,	O
mildly	O
progressed	O
compared	O
to	O
prior.	O
Mild	O
mucosal	O
thickening	O
within	O
the	O
posterior	O
ethmoid	O
air	O
cells	O
and	O
right	O
maxillary	O
sinus,	O
unchanged.	O
No	O
air-fluid	O
levels.	O
___HEST	O
W/CONTRAST	O
Findings	O
suggestive	O
of	O
left	O
lower	O
lobe	O
pneumonia	B-Lower_respiratory_tract_infection
associated	O
to	O
small	O
ipsilateral	O
pleural	O
effusion.	O
The	O
location	O
in	O
the	O
posterior	O
basal	O
segment	O
of	O
the	O
left	O
lower	O
lobe	O
impairs	O
evaluation	O
of	O
this	O
consolidation	O
with	O
single	O
AP	O
radiographs.	O
Recommend	O
follow	O
up	O
in	O
___	O
weeks	O
with	O
either	O
PA	O
and	O
lateral	O
radiographs	O
or	O
chest	O
CT.	O
___BD	O
&	O
PELVIS	O
WITH	O
CO	O
No	O
evidence	O
of	O
acute	O
abnormality	O
involving	O
the	O
abdomen	O
or	O
pelvis.	O
___	O
TTE	O
Normal	O
left	O
ventricular	O
wall	O
thickness	O
and	O
biventricular	O
cavity	O
sizes	O
and	O
regional/global	O
systolic	O
function	O
(EF	O
60%).	O
Mild	O
aortic	O
valve	O
stenosis.	O
Mild	O
mitral	O
regurgitation.	O
Mild-moderate	O
pulmonary	O
artery	O
systolic	O
hypertension.	O
Compared	O
with	O
the	O
prior	O
TTE	O
(images	O
reviewed)	O
of	O
___,	O
the	O
severity	O
of	O
mitral	O
regurgitation,	O
tricuspid	O
regurgitattion	O
and	O
estimated	O
PA	O
systolic	O
pressure	O
are	O
all	O
now	O
lower	O
and	O
regional/global	O
left	O
ventricular	O
systolic	O
function	O
is	O
now	O
improved/normal.	O
PERTINENT	O
MICROBIOLOGY:	O
No	O
growth	O
to	O
date	O
on	O
all	O
blood	O
and	O
urine	O
cultures	O
prior	O
to	O
discharge.	O
PATHOLOGY:	O
Urine,	O
voided:	O
NEGATIVE	O
FOR	O
HIGH-GRADE	O
UROTHELIAL	O
CARCINOMA.	O
BONE	O
MARROW	O
BIOPSY	O
IMMUNOPHENOTYPING:	O
Diagnostic	O
immunophenotypic	O
features	O
of	O
involvement	O
by	O
leukemia	O
are	O
not	O
seen	O
in	O
this	O
specimen.	O
Correlation	O
with	O
clinical,	O
morphologic	O
(see	O
separate	O
pathology	O
report	O
___,	O
cytogenetics	O
studies	O
(see	O
separate	O
cytogenetics	O
report	O
___)	O
and	O
other	O
ancillary	O
findings	O
is	O
recommended.	O
Flow	O
cytometry	O
immunophenotyping	O
may	O
not	O
detect	O
all	O
abnormal	O
populations	O
due	O
to	O
topography,	O
sampling	O
or	O
artifacts	O
of	O
sample	O
preparation.	O
CYTOGENETIC	O
DIAGNOSIS:	O
46,XY[20]	O
Normal	O
male	O
karyotype.	O
DISCHARGE	O
LABS:	O
___	O
12:00AM	O
BLOOD	O
WBC-0.9*	O
RBC-2.38*	O
Hgb-7.1*	O
Hct-21.6*	O
MCV-91	O
MCH-29.8	O
MCHC-32.9	O
RDW-13.9	O
RDWSD-46.1	O
Plt	O
Ct-9*	O
___	O
12:00AM	O
BLOOD	O
Neuts-10*	O
Lymphs-82*	O
Monos-4*	O
Eos-0*	O
Baso-0	O
Atyps-3*	O
Myelos-1*	O
AbsNeut-0.09*	O
AbsLymp-0.77*	O
AbsMono-0.04*	O
AbsEos-0.00*	O
AbsBaso-0.00*	O
___	O
06:30AM	O
BLOOD	O
Plt	O
Ct-24*	O
___	O
12:00AM	O
BLOOD	O
Glucose-125*	O
UreaN-26*	O
Creat-1.0	O
Na-138	O
K-4.1	O
Cl-104	O
HCO3-25	O
AnGap-9*	O
___	O
12:00AM	O
BLOOD	O
ALT-65*	O
AST-49*	O
LD(LDH)-176	O
AlkPhos-82	O
TotBili-0.2	O
___	O
12:00AM	O
BLOOD	O
Calcium-8.4	O
Phos-3.1	O
Mg-1.8	O
UricAcd-2.8*	O
Brief	O
Hospital	O
Course:	O
Mr.	O
___	O
is	O
an	O
___	O
male	O
with	O
MDS	O
transformed	O
to	O
AML	O
on	O
decitabine/venetoclax,	O
diastolic	O
congestive	O
heart	O
failure,	O
polyarticular	O
pseudogout,	O
and	O
myasthenia	O
___	O
(on	O
chronic	O
prednisone)	O
who	O
presented	O
with	O
fever.	O
He	O
was	O
found	O
to	O
have	O
a	O
LLL	O
PNA	B-Lower_respiratory_tract_infection
on	O
CT	O
chest	O
and	O
completed	O
8	O
days	O
of	O
cefepime.	O
TRANSITIONAL	O
ISSUES:	O
[	O
]	O
F/u	O
bone	O
marrow	O
biopsy	O
report	O
[	O
]	O
Patient	O
started	O
on	O
posaconazole	O
this	O
admission,	O
consider	O
additional	O
QTc	O
monitoring	O
by	O
EKG	O
[	O
]	O
Venetoclax	O
dose-reduced	O
to	O
70	O
given	O
initiation	O
of	O
posaconazole	O
[	O
]	O
Consider	O
re-checking	O
renal	O
function,	O
electrolytes	O
given	O
inpatient	O
initiation	O
of	O
lisinopril	O
10MG,	O
consider	O
additional	O
uptitration	O
based	O
on	O
BP	O
[	O
]	O
Consider	O
repeat	O
TTE	O
if	O
having	O
significant	O
weight	O
gain	O
or	O
evidence	O
of	O
volume	O
overload	O
ACUTE	O
ISSUES:	O
#Febrile	O
Neutropenia	O
#LLL	O
PNA	B-Lower_respiratory_tract_infection
Seen	O
on	O
CT	O
chest,	O
initially	O
started	O
on	O
vanc/cefepime,	O
vanc	O
dc'd	O
after	O
MRSA	O
swab	O
negative.	O
Fungal	O
markers	O
were	O
notable	O
for	O
positive	O
B-D-glucan,	O
however	O
as	O
the	O
patient	O
had	O
improved	O
clinically,	O
anti-fungal	O
therapy	O
was	O
not	O
initiated.	O
Completed	O
8	O
days	O
of	O
cefepime,	O
discontinued	O
on	O
___	O
and	O
transitioned	O
to	O
levofloxacin	O
for	O
prophylaxis.	O
Patient	O
subsequently	O
remaining	O
afebrile,	O
clinically	O
well	O
without	O
symptoms	O
of	O
infection	O
for	O
>48H	O
off	O
cefepime	O
prior	O
to	O
discharge.	O
#	O
AML	O
C12	O
Decitabine,	O
Venetoclax	O
newly	O
initiated	O
this	O
cycle.	O
D1	O
=	O
___.	O
Venetoclax	O
held	O
on	O
admission.	O
Prophylactic	O
fluc	O
switched	O
to	O
posaconazole,	O
other	O
home	O
prophylactic	O
medications	O
continued.	O
Given	O
new	O
posaconazole,	O
home	O
venetoclax	O
dose-reduced	O
to	O
70MG.	O
QTc	O
monitored	O
by	O
EKG	O
while	O
on	O
venetoclax,	O
levofloxacin,	O
posaconazole.	O
ANC	O
remained	O
suppressed	O
while	O
inpatient.	O
Bone	O
marrow	O
biopsy	O
performed	O
on	O
___,	O
with	O
core	O
showing	O
hypercellularity	O
but	O
w/o	O
significant	O
blasts	O
on	O
prelim;	O
IHC	O
pending	O
at	O
discharge.	O
#HFpEF	O
On	O
review	O
of	O
weights,	O
appears	O
patient	O
gained	O
~10	O
lbs	O
since	O
last	O
clinic	O
appointment,	O
likely	O
in	O
setting	O
of	O
significant	O
IV	O
inputs.	O
Required	O
intermittent	O
PO	O
lasix	O
20mg	O
for	O
diuresis.	O
Patient	O
subsequently	O
euvolemic	O
without	O
evidence	O
of	O
volume	O
overload	O
for	O
4	O
days	O
off	O
Lasix	O
prior	O
to	O
discharge.	O
#HTN	O
BP	O
elevated	O
to	O
170s	O
on	O
___.	O
Started	O
lisinopril	O
10MG	O
on	O
___,	O
pressures	O
improved.	O
CHRONIC	O
ISSUES:	O
#h/o	O
CDiff	O
infection	O
Was	O
started	O
on	O
PO	O
Vanc	O
BID	O
due	O
to	O
h/o	O
C	O
Diff	O
infection.	O
Has	O
had	O
one	O
instance	O
of	O
this	O
on	O
review	O
of	O
records	O
here.	O
As	O
such,	O
we	O
will	O
discontinue	O
prophylaxis	O
and	O
monitor	O
bowel	O
movements	O
to	O
determine	O
recurrence.	O
No	O
episodes	O
of	O
diarrhea	O
or	O
c/f	O
C.	O
diff	O
this	O
admission.	O
#	O
Anemia/Thrombocytopenia:	O
Secondary	O
to	O
AML	O
and	O
recent	O
chemotherapy.	O
Patient	O
required	O
intermittent	O
platelet	O
transfusions	O
approximately	O
every	O
other	O
day	O
while	O
admitted.	O
Patient	O
and	O
family	O
able	O
to	O
come	O
in	O
for	O
frequent	O
transfusions	O
as	O
outpatient.	O
#	O
Myasthenia	O
___	O
Home	O
steroid	O
dose	O
was	O
doubled	O
in	O
setting	O
of	O
acute	O
infection,	O
then	O
tapered	O
back	O
to	O
home	O
7.5MG	O
prior	O
to	O
discharge.	O
Continued	O
PPI	O
for	O
GI	O
prophylaxis.	O
#	O
Hypothyroidism	O
Continued	O
home	O
levothyroxine.	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Acetaminophen	O
___	O
mg	O
PO	O
BID:PRN	O
Pain	O
-	O
Mild	O
2.	O
Acyclovir	O
400	O
mg	O
PO	O
Q12H	O
3.	O
Atovaquone	O
Suspension	O
1500	O
mg	O
PO	O
DAILY	O
4.	O
Fluconazole	O
200	O
mg	O
PO	O
Q24H	O
5.	O
Levothyroxine	O
Sodium	O
50	O
mcg	O
PO	O
DAILY	O
6.	O
Magnesium	O
Oxide	O
400	O
mg	O
PO	O
TID	O
7.	O
Multivitamins	O
1	O
TAB	O
PO	O
DAILY	O
8.	O
Omeprazole	O
20	O
mg	O
PO	O
DAILY	O
9.	O
Calcium	O
600	O
+	O
D(3)	O
(calcium	O
carbonate-vitamin	O
D3)	O
600	O
mg(1,500mg)	O
-400	O
unit	O
oral	O
DAILY	O
10.	O
Senna	O
8.6	O
mg	O
PO	O
QHS	O
11.	O
Psyllium	O
Powder	O
1	O
PKT	O
PO	O
DAILY	O
12.	O
PredniSONE	O
7.5	O
mg	O
PO	O
DAILY	O
13.	O
Venetoclax	O
200	O
mg	O
PO	O
DAILY	O
14.	O
Allopurinol	O
___	O
mg	O
PO	O
DAILY	O
Discharge	O
Medications:	O
1.	O
Levofloxacin	O
500	O
mg	O
PO	O
Q24H	O
RX	O
*levofloxacin	O
500	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
once	O
a	O
day	O
Disp	O
#*30	O
Tablet	O
Refills:*0	O
2.	O
Lisinopril	O
10	O
mg	O
PO	O
DAILY	O
RX	O
*lisinopril	O
10	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
once	O
a	O
day	O
Disp	O
#*30	O
Tablet	O
Refills:*0	O
3.	O
Posaconazole	O
Delayed	O
Release	O
Tablet	O
300	O
mg	O
PO	O
DAILY	O
4.	O
Venetoclax	O
70	O
mg	O
PO	O
DAILY	O
RX	O
*venetoclax	O
[Venclexta]	O
50	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
once	O
a	O
day	O
Disp	O
#*30	O
Tablet	O
Refills:*0	O
RX	O
*venetoclax	O
[Venclexta]	O
10	O
mg	O
2	O
tablet(s)	O
by	O
mouth	O
once	O
a	O
day	O
Disp	O
#*60	O
Tablet	O
Refills:*0	O
5.	O
Acetaminophen	O
___	O
mg	O
PO	O
BID:PRN	O
Pain	O
-	O
Mild	O
6.	O
Acyclovir	O
400	O
mg	O
PO	O
Q12H	O
7.	O
Allopurinol	O
___	O
mg	O
PO	O
DAILY	O
8.	O
Atovaquone	O
Suspension	O
1500	O
mg	O
PO	O
DAILY	O
9.	O
Calcium	O
600	O
+	O
D(3)	O
(calcium	O
carbonate-vitamin	O
D3)	O
600	O
mg(1,500mg)	O
-400	O
unit	O
oral	O
DAILY	O
10.	O
Levothyroxine	O
Sodium	O
50	O
mcg	O
PO	O
DAILY	O
11.	O
Magnesium	O
Oxide	O
400	O
mg	O
PO	O
TID	O
12.	O
Multivitamins	O
1	O
TAB	O
PO	O
DAILY	O
13.	O
Omeprazole	O
20	O
mg	O
PO	O
DAILY	O
14.	O
PredniSONE	O
7.5	O
mg	O
PO	O
DAILY	O
15.	O
Psyllium	O
Powder	O
1	O
PKT	O
PO	O
DAILY	O
16.	O
Senna	O
8.6	O
mg	O
PO	O
QHS	O
Discharge	O
Disposition:	O
Home	O
Discharge	O
Diagnosis:	O
PRIMARY	O
DIAGNOSES	O
#Febrile	O
Neutropenia	O
#Pneumonia	I-Lower_respiratory_tract_infection
SECONDARY	O
DIAGNOSES	O
#AML	O
#HFpEF	O
#Myasthenia	O
___	O
#HTN	O
#ypothyroidism	O
Discharge	O
Condition:	O
Mental	O
Status:	O
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Independently_mobile
-	B-Independently_mobile
Independent.	B-Independently_mobile
Discharge	O
Instructions:	O
Dear	O
___	O
___	O
you	O
for	O
coming	O
to	O
___	O
for	O
your	O
care.	O
Please	O
read	O
the	O
following	O
instructions	O
carefully:	O
WHY	O
WAS	O
I	O
ADMITTED	O
TO	O
THE	O
HOSPITAL?	O
-	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
because	O
you	O
had	O
a	O
fever	O
while	O
your	O
blood	O
counts	O
were	O
low.	O
WHAT	O
WAS	O
DONE	O
FOR	O
ME	O
WHILE	O
I	O
WAS	O
HERE?	O
-	O
You	O
were	O
found	O
to	O
have	O
a	O
pneumonia	B-Lower_respiratory_tract_infection
-	O
You	O
were	O
given	O
antibiotics	O
for	O
your	O
infection	O
-	O
We	O
started	O
you	O
on	O
blood	O
pressure	O
medications	O
-	O
You	O
had	O
a	O
bone	O
marrow	O
biopsy	O
-	O
You	O
were	O
started	O
on	O
new	O
medications	O
to	O
prevent	O
infection	O
in	O
the	O
setting	O
of	O
neutropenia	O
WHAT	O
DO	O
I	O
NEED	O
TO	O
DO	O
WHEN	O
I	O
LEAVE	O
THE	O
HOSPITAL?	O
-	O
Please	O
take	O
your	O
medications	O
as	O
prescribed	O
-	O
Please	O
keep	O
your	O
follow-ups	O
as	O
listed	O
below	O
-	O
If	O
you	O
develop	O
a	O
fever	O
of	O
100.4	O
or	O
greater,	O
please	O
call	O
your	O
oncologist	O
and	O
seek	O
urgent	O
medical	O
attention	O
Followup	O
Instructions:	O
___	O

